Shenoy Dinesh, Little Steven, Langer Robert, Amiji Mansoor
Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts 02115, USA.
Pharm Res. 2005 Dec;22(12):2107-14. doi: 10.1007/s11095-005-8343-0. Epub 2005 Nov 3.
This study was carried out to determine the biodistribution profiles and tumor localization potential of poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) as a novel, pH-sensitive biodegradable polymeric nanoparticulate system for tumor-targeted drug delivery.
The biodistribution studies of PEO-modified PbAE and PEO-modified poly(epsilon-caprolactone) (PCL), a non-pH-sensitive polymer, nanoparticle systems were carried out in normal mice using 111indium-oxine [111In] as a lipophilic radiolabel encapsulated within the polymeric matrix, and the distribution of the nanoparticles was studied in plasma and all the vital organs following intravenous administration. Solid tumors were developed on nude mice using human ovarian carcinoma xenograft (SKOV-3) and the change in concentrations of tritium [3H]-labeled paclitaxel encapsulated in polymeric nanoparticles was examined in blood, tumor mass, and liver.
Study in normal mice with a gamma-emitting isotope [111In] provided a thorough biodistribution analysis of the PEO-modified nanoparticulate carrier systems, whereas 3H-paclitaxel was useful to understand the change in concentration and tumor localization of anticancer compound directly in major sites of distribution. Both PEO-PbAE and PEO-PCL nanoparticles showed long systemic circulating properties by virtue of surface modification with PEO-containing triblock block copolymer (Pluronic stabilizer. Although the PCL nanoparticles showed higher uptake by the reticuloendothelial system, the PbAE nanoparticles effectively delivered the encapsulated payload into the tumor mass.
PEO-modified PbAE nanoparticles showed considerable passive tumor targeting potential in early stages of biodistribution via the enhanced permeation and retention (EPR) mechanism. This prompts a detailed biodistribution profiling of the nanocarrier for prolonged periods to provide conclusive evidence for superiority of the delivery system.
本研究旨在确定聚环氧乙烷(PEO)修饰的聚β-氨基酯(PbAE)作为一种新型的、pH敏感的可生物降解聚合物纳米颗粒系统用于肿瘤靶向给药的生物分布特征和肿瘤定位潜力。
使用111铟-氧嗪[111In]作为包裹在聚合物基质中的亲脂性放射性标记物,在正常小鼠中对PEO修饰的PbAE和PEO修饰的聚己内酯(PCL,一种非pH敏感聚合物)纳米颗粒系统进行生物分布研究,并在静脉给药后研究纳米颗粒在血浆和所有重要器官中的分布。使用人卵巢癌异种移植瘤(SKOV-3)在裸鼠身上形成实体瘤,并检测包裹在聚合物纳米颗粒中的氚[3H]标记紫杉醇在血液、肿瘤组织和肝脏中的浓度变化。
使用发射γ射线的同位素[111In]对正常小鼠进行的研究提供了对PEO修饰的纳米颗粒载体系统的全面生物分布分析,而3H-紫杉醇有助于直接了解抗癌化合物在主要分布部位的浓度变化和肿瘤定位。PEO-PbAE和PEO-PCL纳米颗粒由于用含PEO的三嵌段共聚物(普朗尼克稳定剂)进行表面修饰而表现出较长的全身循环特性。尽管PCL纳米颗粒被网状内皮系统摄取的量更高,但PbAE纳米颗粒有效地将包裹的药物输送到肿瘤组织中。
PEO修饰的PbAE纳米颗粒在生物分布的早期阶段通过增强渗透和滞留(EPR)机制显示出相当大的被动肿瘤靶向潜力。这促使对纳米载体进行长时间的详细生物分布分析,以提供该给药系统优越性的确凿证据。